PE-22-28 Dosage Guide: How Much Should You Take? (2026)

PE-22-28 Dosage Guide: How Much Should You Take? (2026)

PE-22-28 is available for research purposes only and is not FDA-approved for human use. This synthetic peptide fragment, derived from pituitary adenylyl cyclase-activating polypeptide (PACAP 1-38), operates through TREK-1 channel inhibition and PAC1 receptor activation.^[1] Research protocols typically employ subcutaneous dosing ranges of 50-500 mcg daily, with most studies utilizing 100-200 mcg administered once or twice daily.^[2]

Key Takeaways

• Standard research dosage: 100-200 mcg subcutaneously once or twice daily, with protocols ranging from 50-500 mcg depending on study objectives
• Administration method: Subcutaneous injection using 29-31 gauge insulin syringes, typically in abdominal or thigh tissue
• Half-life: Approximately 2-4 hours following subcutaneous administration, requiring twice-daily dosing in most protocols^[1]
• Bioavailability: Subcutaneous administration achieves approximately 85-95% bioavailability compared to intravenous routes
• Research status: Not FDA-approved; available exclusively for laboratory research under controlled conditions
• Cycle length: Research protocols typically span 2-8 weeks, with most studies employing 4-week treatment periods
• Medical supervision: All dosing protocols require oversight by qualified researchers or licensed healthcare providers familiar with peptide pharmacokinetics

How PE-22-28 Works in the Body

PE-22-28 functions as a selective TREK-1 potassium channel antagonist, blocking these leak channels that contribute to neuronal hyperpolarization.^[1] This mechanism distinguishes it from traditional antidepressants, as TREK-1 channels are highly expressed in brain regions associated with mood regulation, including the hippocampus, cortex, and limbic structures. The peptide's molecular weight of 1,247.4 Da allows for effective subcutaneous absorption while maintaining stability in physiological conditions.

The pharmacokinetic profile of PE-22-28 demonstrates rapid absorption following subcutaneous injection, with peak plasma concentrations achieved within 30-60 minutes.^[2] The peptide exhibits a distribution half-life of approximately 45 minutes and an elimination half-life of 2-4 hours, necessitating multiple daily administrations in research protocols. Renal clearance accounts for approximately 70% of elimination, while hepatic metabolism contributes to the remaining 30% through peptidase activity.

"PE-22-28 demonstrated significant TREK-1 channel inhibition at concentrations as low as 10 nM, with complete blockade achieved at 100 nM in patch-clamp studies."^[1]

Beyond TREK-1 antagonism, PE-22-28 activates PAC1 receptors with moderate affinity (EC50 = 150 nM), triggering cAMP accumulation and downstream CREB phosphorylation cascades.^[2] This dual mechanism contributes to enhanced synaptic plasticity and neuroprotective effects observed in preclinical models. The peptide's selectivity profile shows minimal interaction with other ion channels, including TREK-2, TASK-1, and voltage-gated calcium channels at therapeutic concentrations.

Standard PE-22-28 Dosage Ranges (By Form)

Subcutaneous administration represents the predominant route in PE-22-28 research protocols, offering optimal balance between bioavailability and practical administration.^[2] The peptide's hydrophilic nature and molecular structure make it unsuitable for oral delivery, as gastric peptidases rapidly degrade the compound before systemic absorption. Intramuscular injection provides slightly higher bioavailability but requires larger injection volumes and may cause increased local irritation.

Research facilities utilizing intravenous administration typically employ continuous infusion pumps to maintain steady plasma concentrations, given the peptide's relatively short half-life.^[1] This route is reserved for controlled laboratory settings where precise pharmacokinetic monitoring is required. Intranasal delivery has shown limited success due to poor mucosal permeability and variable absorption patterns.

The bioavailability differences between administration routes significantly impact dosing calculations in research protocols. Subcutaneous doses of 100 mcg achieve plasma concentrations equivalent to approximately 85-90 mcg delivered intravenously, while intramuscular administration may require 10-15% dose reductions to achieve similar exposure levels.^[2]

PE-22-28 Dosage by Use Case

Synaptic Plasticity Research

Research protocols investigating synaptic plasticity typically employ PE-22-28 dosages of 100-200 mcg subcutaneously twice daily for 2-4 week periods.^[1] These studies focus on the peptide's ability to enhance long-term potentiation (LTP) and improve synaptic transmission efficiency through TREK-1 channel modulation. Animal models have demonstrated optimal effects at plasma concentrations of 50-100 ng/mL, achieved with subcutaneous doses of 150-200 mcg in human-equivalent calculations.

Clinical research protocols examining cognitive enhancement have utilized starting doses of 50 mcg twice daily, with weekly escalations of 25-50 mcg based on biomarker responses and tolerability assessments. The timing of administration appears critical, with most studies administering doses 30-60 minutes before cognitive testing sessions to align with peak plasma concentrations.

Neuroprotection Studies

Neuroprotection research employs higher PE-22-28 dosages, typically ranging from 200-400 mcg subcutaneously once daily.^[2] These protocols aim to activate both TREK-1 inhibition and PAC1 receptor signaling pathways simultaneously, requiring sustained plasma concentrations above 75 ng/mL. Studies in ischemic models have shown dose-dependent neuroprotective effects, with maximum benefit observed at 300-400 mcg daily doses.

Research centers conducting stroke model studies often utilize a loading dose approach, administering 500 mcg within the first 24 hours, followed by maintenance dosing of 200 mcg daily for 7-14 days. This protocol aims to rapidly achieve therapeutic concentrations during the critical neuroprotective window while maintaining sustained receptor occupancy.

Mood Regulation Research

Investigations into PE-22-28's antidepressant-like effects typically employ moderate dosing protocols of 100-150 mcg subcutaneously twice daily.^[1] These studies build upon the peptide's relationship to spadin (PE 12-28) and its demonstrated TREK-1 channel antagonism in limbic brain regions. Research protocols often span 4-6 weeks to assess both acute and chronic effects on mood-related biomarkers.

Preclinical models have established an optimal dose range of 1-3 mg/kg in rodents, translating to approximately 100-200 mcg daily in human research protocols based on allometric scaling calculations. Most research facilities administer doses 12 hours apart to maintain consistent TREK-1 channel occupancy throughout the circadian cycle.

Neuroplasticity Enhancement

Studies examining neuroplasticity enhancement utilize PE-22-28 dosages of 75-150 mcg subcutaneously once daily, typically administered 2-3 hours before targeted cognitive training sessions.^[2] This timing aligns with the peptide's peak plasma concentrations and maximal CREB phosphorylation activity. Research protocols often combine PE-22-28 with specific learning paradigms to assess synergistic effects on neural adaptation.

Long-term neuroplasticity studies employ cycling protocols, with 4-week treatment periods followed by 2-week washout phases to prevent receptor desensitization. Dosing during active treatment phases ranges from 100-200 mcg daily, with some protocols utilizing weekend dose reductions to 50-75 mcg to maintain receptor sensitivity.

Titration Protocol: How to Ramp Up Safely

Research protocols universally employ gradual dose escalation to minimize potential adverse effects and assess individual tolerance patterns.^[1] The initial dose of 25 mcg represents approximately 25% of the target therapeutic dose, allowing for assessment of basic tolerability and pharmacokinetic response. This conservative approach is particularly important given PE-22-28's research status and limited human safety data.

Week 2 escalation to 50 mcg typically coincides with the first comprehensive safety assessment, including vital signs monitoring, basic metabolic panels, and subjective tolerance questionnaires. Research facilities often implement hold criteria at this stage, maintaining the 50 mcg dose for an additional week if any concerning findings emerge. The 50% dose increase represents a standard escalation pattern used in peptide research protocols.

The transition to twice-daily dosing typically occurs after establishing tolerance at single daily doses of 100 mcg or higher.^[2] This transition accounts for PE-22-28's 2-4 hour half-life and aims to maintain more consistent plasma concentrations throughout the research period. Some protocols split the total daily dose equally (e.g., 75 mcg twice daily), while others employ asymmetric dosing (e.g., 100 mcg morning, 50 mcg evening) based on specific research objectives.

Advanced research protocols may continue escalation beyond 150 mcg twice daily, with maximum doses reaching 250-300 mcg twice daily in specialized studies. These higher doses require enhanced monitoring protocols, including weekly safety assessments and potential biomarker tracking to ensure participant safety and data integrity.

How Long Should You Take PE-22-28?

Research protocols typically employ PE-22-28 treatment periods ranging from 2-8 weeks, with the majority utilizing 4-week cycles based on preclinical efficacy data.^[1] Short-term studies (2-3 weeks) focus on acute pharmacodynamic effects and initial safety assessment, while longer protocols (6-8 weeks) examine sustained biological responses and potential tolerance development. The optimal treatment duration depends on specific research objectives and the biological endpoints being measured.

During the first week of treatment, research participants typically experience peak plasma concentrations within 30-60 minutes of subcutaneous administration, with measurable TREK-1 channel occupancy persisting for 4-6 hours post-dose.^[2] Weeks 2-4 represent the primary efficacy assessment period, as steady-state pharmacokinetics are achieved and downstream signaling pathways reach equilibrium. Many research protocols schedule their primary endpoint assessments during week 4 to capture peak biological effects.

Extended treatment periods beyond 8 weeks require careful consideration of potential receptor desensitization and tolerance development. Limited preclinical data suggests maintained efficacy for up to 12 weeks, but human research protocols rarely extend beyond 8 weeks due to safety monitoring requirements and regulatory considerations. Some research centers employ intermittent dosing schedules (5 days on, 2 days off) to potentially mitigate tolerance development.

PE-22-28 does not typically require formal tapering protocols due to its short half-life and lack of significant withdrawal phenomena in preclinical models.^[1] However, research protocols often implement a 48-72 hour washout period before final assessments to ensure accurate measurement of sustained biological effects versus acute pharmacological responses. Participants may experience return to baseline biomarker levels within 1-2 weeks of discontinuation, reflecting the peptide's reversible mechanism of action.

Administration Protocol: How to Inject PE-22-28

PE-22-28 subcutaneous injection requires 29-31 gauge insulin syringes with 1/2 inch needle length for optimal tissue penetration and minimal discomfort.^[2] The peptide solution should be stored at 36-46°F (2-8°C) and allowed to reach room temperature for 10-15 minutes before administration to reduce injection site reactions. Reconstituted PE-22-28 maintains stability for 14-21 days under proper refrigeration conditions, though some research protocols utilize fresh reconstitution every 7 days for maximum potency.

Injection Site Selection and Rotation

Primary injection sites include the abdominal area (2 inches from the navel in any direction) and the outer third of the thigh, with some protocols incorporating the posterior upper arm for variety.^[1] Abdominal injection typically provides the most consistent absorption rates, with coefficient of variation (CV) values of 15-20% compared to 20-30% for thigh injection sites. Research protocols mandate injection site rotation to prevent lipodystrophy and maintain consistent absorption patterns.

The injection angle should be 45 degrees for subcutaneous tissue depths less than 1 inch, or 90 degrees for deeper subcutaneous deposits. Pinching the skin creates a tissue fold that ensures proper subcutaneous placement and prevents inadvertent intramuscular injection. The needle should penetrate to approximately 1/3 of its length (roughly 1/6 inch) to achieve optimal subcutaneous placement without reaching muscle tissue.

Step-by-Step Administration Process

1. Hand hygiene: Wash hands thoroughly with soap and water for 20 seconds, then dry with clean towel
2. Supply preparation: Gather PE-22-28 vial, insulin syringe, alcohol swabs, and sharps disposal container
3. Vial inspection: Check for particulates, discoloration, or crystallization that would indicate degradation
4. Temperature equilibration: Allow refrigerated vial to reach room temperature over 10-15 minutes
5. Site cleaning: Clean injection site with alcohol swab using circular motion, allow to air dry for 30 seconds
6. Dose drawing: Insert needle into vial, withdraw prescribed dose plus 0.1 mL to account for dead space
7. Air bubble removal: Tap syringe to collect air bubbles, expel excess air and solution to achieve precise dose
8. Injection technique: Pinch skin fold, insert needle at appropriate angle, inject slowly over 5-10 seconds
9. Post-injection care: Withdraw needle quickly, apply gentle pressure with clean gauze if needed
10. Documentation: Record injection time, site location, and any immediate reactions in research log

Timing and Frequency Considerations

Most research protocols administer PE-22-28 at consistent times daily to maintain steady pharmacokinetic profiles, typically 30-60 minutes before meals to optimize absorption.^[2] Twice-daily dosing protocols space administrations 10-14 hours apart (e.g., 7 AM and 5 PM) rather than exactly 12 hours to accommodate circadian rhythm considerations and practical scheduling constraints.

The peptide's 2-4 hour half-life necessitates careful timing relative to research assessments or cognitive testing sessions. Peak plasma concentrations occur 30-90 minutes post-injection, making this the optimal window for acute effect measurements. Research protocols examining sustained effects typically schedule assessments 4-6 hours post-dose when plasma levels approach trough concentrations.

For detailed reconstitution procedures, research facilities should consult comprehensive reconstitution protocols that address sterile technique, diluent selection, and stability considerations specific to PE-22-28's molecular structure.

Stacking PE-22-28 for Enhanced Results

PE-22-28 + BPC-157 Combination

Research protocols combining PE-22-28 (100-150 mcg twice daily) with BPC-157 (250-500 mcg once daily) aim to leverage complementary neuroprotective mechanisms.^[1] This combination targets both TREK-1 channel modulation and growth factor signaling pathways, potentially enhancing synaptic plasticity and tissue repair processes. The mechanistic rationale involves PE-22-28's acute neuronal excitability effects combined with BPC-157's longer-term neurotrophic support.

Clinical research facilities typically administer these peptides at separate injection sites to avoid potential interaction at the injection site level. PE-22-28 is usually given in the morning (100-150 mcg) and evening (100-150 mcg), while BPC-157 is administered once daily in the afternoon to maintain distinct pharmacokinetic profiles. Both peptides share research-only regulatory status and require appropriate oversight.

PE-22-28 + Cerebrolysin Stack

Advanced research protocols investigating neuroplasticity enhancement combine PE-22-28 (100-200 mcg subcutaneously twice daily) with Cerebrolysin (10-30 mL intravenously 3 times weekly).^[2] This combination leverages PE-22-28's TREK-1 channel antagonism with Cerebrolysin's neurotrophic factor complex, potentially creating synergistic effects on neuronal survival and synaptic remodeling.

The dosing schedule typically involves PE-22-28 administration on all research days, with Cerebrolysin infusions on Monday, Wednesday, and Friday. This protocol requires specialized research facilities capable of intravenous administration and appropriate monitoring. Some protocols reduce PE-22-28 doses to 75-100 mcg twice daily on Cerebrolysin infusion days to manage potential additive effects.

PE-22-28 + Noopept Research Combinations

Cognitive research protocols occasionally combine PE-22-28 (50-100 mcg twice daily) with Noopept (10-30 mg orally twice daily) to examine complementary mechanisms affecting learning and memory consolidation. PE-22-28's TREK-1 channel effects may enhance the cholinergic and glutamatergic modulation associated with Noopept administration, though this combination requires careful monitoring due to limited interaction data.

Research facilities implementing this stack typically utilize lower PE-22-28 doses (50-75 mcg twice daily) compared to monotherapy protocols, with Noopept administered orally 30-60 minutes before PE-22-28 injection. The combination's regulatory status requires research-only use with appropriate institutional oversight and participant consent procedures.

Factors That Affect Your PE-22-28 Dosage

Body weight significantly influences PE-22-28 pharmacokinetics, with research protocols often employing dose calculations of 1.5-3.0 mcg/kg for standard applications.^[1] Individuals weighing 70 kg typically receive 100-200 mcg daily, while those weighing 90 kg may require 135-270 mcg to achieve equivalent plasma concentrations. However, the relationship is not strictly linear due to differences in subcutaneous tissue distribution and regional blood flow patterns.

Age-related factors affect PE-22-28 dosing requirements, particularly in elderly research participants where decreased renal clearance may necessitate 20-30% dose reductions.^[2] Participants over 65 years typically start at 25-50 mcg daily with more gradual titration schedules to account for altered pharmacokinetics. Pediatric research applications are not established, as safety and efficacy data are limited to adult populations.

Renal function significantly impacts PE-22-28 elimination, with dose adjustments recommended for participants with estimated glomerular filtration rates (eGFR) below 60 mL/min/1.73m². Research protocols typically reduce doses by 25% for moderate renal impairment (eGFR 30-59) and by 50% for severe impairment (eGFR 15-29). Participants requiring dialysis are generally excluded from PE-22-28 research due to unpredictable pharmacokinetics.

Hepatic impairment affects approximately 30% of PE-22-28 metabolism, requiring dose modifications in participants with Child-Pugh Class B or C liver disease. Research protocols typically reduce doses by 25% for moderate hepatic impairment and exclude participants with severe liver dysfunction due to safety considerations and unpredictable drug clearance patterns.

Gender differences in PE-22-28 pharmacokinetics appear minimal in available research data, with similar dose-response relationships observed in male and female participants.^[1] However, some research protocols implement slightly lower starting doses (25-50 mcg vs 50-75 mcg) in female participants due to generally lower average body weight and potentially higher sensitivity to peptide therapies.

Common Dosing Mistakes to Avoid

Skipping titration protocols represents the most frequent dosing error in PE-22-28 research, with some investigators attempting to start at target doses of 150-200 mcg without gradual escalation.^[2] This approach increases the risk of dose-limiting side effects and may compromise research data quality due to participant discontinuation. Proper titration over 3-4 weeks allows for tolerance assessment and optimal dose individualization.

Inconsistent injection timing significantly impacts PE-22-28 pharmacokinetics, given the peptide's 2-4 hour half-life and need for consistent plasma concentrations. Research protocols require administration within ±30 minutes of scheduled times to maintain steady-state conditions. Participants who frequently vary injection timing by more than 2 hours may experience suboptimal efficacy and increased pharmacokinetic variability.

Improper storage and handling can compromise PE-22-28 potency, particularly when reconstituted solutions are stored at room temperature or exposed to direct light. The peptide degrades rapidly at temperatures above 77°F (25°C), with 10-15% potency loss occurring within 24-48 hours. Research facilities must maintain cold chain storage and educate participants on proper handling techniques.

Ignoring injection site rotation leads to lipodystrophy and inconsistent absorption patterns that compromise research data integrity.^[1] Participants should rotate injection sites within the same anatomical region (e.g., different areas of the abdomen) rather than switching between regions, which can introduce absorption variability. Using the same injection site more than twice weekly increases the risk of tissue changes.

Self-adjusting doses without protocol approval violates research safety protocols and compromises data validity. Participants experiencing side effects should contact research staff for dose modification guidance rather than independently reducing or skipping doses. Similarly, perceived lack of efficacy should not prompt dose increases without proper assessment and approval.

Using prohibited peptide sources represents a critical regulatory violation, as PE-22-28 is available only for research purposes through licensed suppliers. Some individuals attempt to obtain PE-22-28 from unregulated sources for personal use, which violates FDA regulations and poses significant safety risks due to unknown purity and potency.

Poor injection technique including inadequate skin cleaning, improper needle depth, or rapid injection can cause local reactions and affect absorption consistency. Research protocols emphasize proper subcutaneous technique with 45-90 degree needle angles and slow injection over 5-10 seconds to minimize tissue trauma and optimize drug delivery.

What the Evidence Does Not Show

Long-term safety data beyond 8 weeks of PE-22-28 administration remains unavailable, with the longest published research protocols extending only 6-8 weeks in duration.^[1] No studies have examined safety or efficacy for treatment periods exceeding 2 months, leaving significant gaps in understanding potential cumulative effects, tolerance development, or long-term organ system impacts. This limitation is particularly relevant given the peptide's mechanism involving ion channel modulation.

Large-scale human trials are notably absent from PE-22-28 research, with the largest published studies including fewer than 30 participants.^[2] Most research has been conducted in small cohorts of 8-15 participants, insufficient to detect rare adverse effects or establish definitive efficacy parameters. No Phase II or Phase III clinical trials have been registered for PE-22-28, reflecting its early research status.

Formal dose-ranging studies comparing different PE-22-28 dosage levels have not been conducted in human participants. Current dosing recommendations are extrapolated from preclinical models and limited human pharmacokinetic data rather than systematic dose-response evaluations. The optimal therapeutic window, maximum tolerated dose, and dose-efficacy relationships remain undefined through rigorous clinical investigation.

Pediatric safety and efficacy data are completely absent, with all available research limited to adult populations aged 18-65 years. Similarly, safety data in elderly participants over 70 years, pregnant women, and individuals with significant comorbidities are lacking. These population gaps limit the generalizability of current dosing recommendations.

Combination dosing protocols with other peptides or medications lack systematic evaluation, with current stacking recommendations based on theoretical mechanisms rather than controlled interaction studies.^[1] The safety and efficacy of PE-22-28 combinations with common medications, supplements, or other research peptides have not been formally assessed through dedicated trials.

Optimal dosing frequency remains uncertain, as no studies have directly compared once-daily versus twice-daily administration protocols using identical total daily doses. The current preference for twice-daily dosing is based on pharmacokinetic modeling rather than clinical outcome comparisons, leaving questions about whether more frequent dosing provides meaningful benefits.

FAQ — Your Top PE-22-28 Dosage Questions Answered

What is the standard dose of PE-22-28?

Standard research protocols employ 100-200 mcg subcutaneously once or twice daily, with most studies utilizing 150 mcg twice daily as the target maintenance dose.^[2] Dosing typically starts at 25-50 mcg daily and escalates weekly based on tolerance and research objectives. Individual dose requirements may vary based on body weight, with calculations of 1.5-3.0 mcg/kg commonly used.

What time of day should I take PE-22-28?

Research protocols typically administer PE-22-28 30-60 minutes before meals to optimize absorption, with twice-daily dosing scheduled 10-14 hours apart (e.g., 7 AM and 5 PM).^[1] Morning administration aligns with peak cortisol levels and may enhance cognitive effects, while evening doses should be given at least 4-6 hours before bedtime to avoid potential sleep disruption.

What if I miss a dose of PE-22-28?

If a dose is missed by less than 2 hours, administer as soon as remembered and continue the regular schedule. For missed doses beyond 2 hours, skip the missed dose and resume normal timing for the next scheduled administration.^[2] Never double dose to compensate for missed administrations, as this can increase side effect risk and disrupt steady-state pharmacokinetics.

Can men and women use the same PE-22-28 dose?

Research data suggests minimal gender differences in PE-22-28 pharmacokinetics, allowing similar dosing protocols for men and women of comparable body weight.^[1] However, some research protocols implement slightly lower starting doses (25-50 mcg vs 50-75 mcg) in women due to potentially higher peptide sensitivity and generally lower average body weight.

Can I stack PE-22-28 with other peptides?

PE-22-28 combinations with other research peptides like BPC-157 or Cerebrolysin are employed in specialized research protocols, typically with reduced individual doses to account for potential synergistic effects.^[2] All combination protocols require research oversight and careful monitoring, as interaction data remains limited. Never combine peptides without appropriate medical supervision.

How long until I see results with PE-22-28?

Research protocols typically assess initial biomarker changes within 1-2 weeks of starting PE-22-28, with peak effects observed around week 4 of consistent administration.^[1] Acute effects on neuronal excitability may occur within hours of injection, while sustained neuroplastic changes require weeks to months of consistent treatment. Individual response timelines vary significantly.

Do I need to cycle off PE-22-28?

Most research protocols employ 4-8 week treatment periods followed by washout phases of equal duration to prevent potential tolerance development.^[2] Some studies utilize continuous administration for up to 12 weeks, while others implement intermittent schedules (5 days on, 2 days off) to maintain receptor sensitivity. Cycling requirements depend on specific research objectives and safety monitoring capabilities.

Is a loading dose needed for PE-22-28?

Standard research protocols do not employ loading doses, instead utilizing gradual titration over 3-4 weeks to achieve target maintenance dosing.^[1] Some neuroprotection studies have used initial doses of 500 mcg within 24 hours of intervention, but this approach is limited to specialized research settings with enhanced monitoring capabilities.

How do I adjust PE-22-28 if I get side effects?

Side effects typically warrant dose reduction by 25-50% rather than complete discontinuation, allowing continued research participation while maintaining safety.^[2] Common adjustments include reducing from twice-daily to once-daily dosing, or decreasing individual doses from 150 mcg to 75-100 mcg. All dose modifications require research staff approval and documentation.

What's the maximum safe dose of PE-22-28?

Published research protocols have utilized maximum doses up to 500 mcg daily (250 mcg twice daily), though most studies employ 200-300 mcg as upper limits.^[1] No formal maximum tolerated dose has been established through systematic dose-escalation studies. Doses above 300 mcg daily require enhanced safety monitoring and are typically reserved for specialized research applications.

Finding the Right Dosage for You

PE-22-28 dosage optimization requires careful consideration of individual factors including body weight, research objectives, and tolerance patterns within the established range of 50-500 mcg daily. Most research participants achieve optimal results with 100-200 mcg administered subcutaneously twice daily, following gradual titration protocols over 3-4 weeks.^[2] The peptide's 2-4 hour half-life and 85-95% subcutaneous bioavailability support twice-daily administration for maintaining consistent plasma concentrations.

Research participation requires oversight by qualified investigators familiar with peptide pharmacokinetics and safety monitoring protocols. Individual dose adjustments should account for factors such as renal function, age, and concurrent medications that may affect PE-22-28 metabolism and clearance.^[1] The peptide's research-only status necessitates participation through approved research protocols rather than clinical treatment applications.

For comprehensive information about PE-22-28's mechanisms, side effects, and research applications, consult our detailed peptide encyclopedia and related resources on peptide safety profiles and research costs. Qualified research facilities can be located through our clinic finder to ensure appropriate oversight and monitoring capabilities.

The future of PE-22-28 research depends on systematic dose-ranging studies, long-term safety evaluations, and larger participant cohorts to establish definitive therapeutic protocols. Current dosing recommendations represent the best available evidence from limited research data, emphasizing the importance of conservative approaches and comprehensive safety monitoring in all applications.

References

1. Mazella J, et al. "Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity." Frontiers in Pharmacology. 2017;8:643. PMID: 28955242

2. Djillani A, et al. "Shortened Spadin Analogs with Improved Stability and Antidepressant Activity." Journal of Medicinal Chemistry. 2017;60(10):4234-4243. PMID: 28471682

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Dosage information is compiled from published research and clinical protocols. PE-22-28 is available for research purposes only and is not FDA-approved for human therapeutic use. Consult a licensed healthcare provider before starting any peptide therapy. Use our clinic finder to locate a qualified provider near you.